Thymoquinone protects against experimental colitis in rats

Area of Science:

• Pharmacology
• Gastroenterology
• Natural Product Chemistry

Background:

• Colitis is a significant inflammatory condition affecting the colon.
• Acetic acid-induced colitis in rats serves as a standard model for studying human ulcerative colitis.
• Investigating natural compounds for therapeutic potential is crucial for developing new treatments.

Purpose of the Study:

• To evaluate the protective effects of thymoquinone against acetic acid-induced colitis in a rat model.
• To compare the efficacy of thymoquinone with a conventional drug, sulfasalazine.
• To explore the potential mechanisms underlying thymoquinone's therapeutic action.

Main Methods:

• Colitis was induced in rats via intracolonic administration of 3% acetic acid.
• Rats were pretreated with varying doses of thymoquinone (5 and 10 mg/kg) or sulfasalazine (500 mg/kg).
• Macroscopic, histopathological, and biochemical parameters (myeloperoxidase activity, reduced glutathione, PAF, histamine) were assessed.

Main Results:

• Thymoquinone (10 mg/kg) provided complete protection against colitis, surpassing sulfasalazine's efficacy.
• A lower dose of thymoquinone (5 mg/kg) offered partial protection.
• Thymoquinone treatment reversed biochemical and histopathological damage towards control levels.

Conclusions:

• Thymoquinone exhibits significant beneficial effects in an experimental model of colitis.
• The protective mechanism of thymoquinone may involve antioxidant properties.
• Thymoquinone represents a promising therapeutic agent for managing colitis.